Premium
Tritiation of the cannabinoid receptor antagonist SR144528 involving lithium aluminum tritide reduction; assessment of the kinetic isotope effect by 3 H‐NMR
Author(s) -
Seltzman Herbert H.,
Foster Matthew C.,
Wyrick Christopher D.,
Burgess Jason P.,
Ivy Carroll F.
Publication year - 2005
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.952
Subject(s) - chemistry , tritium , antagonist , lithium (medication) , kinetic isotope effect , aluminum hydride , radiochemistry , catalysis , nuclear chemistry , organic chemistry , receptor , biochemistry , deuterium , medicine , physics , quantum mechanics , nuclear physics , endocrinology , methoxide
The cannabinoid receptor antagonist SR144528 was synthesized by an approach that enabled the incorporation of high specific activity tritium label while circumventing the lability of the target compound to catalytic hydrogenation. Lithium aluminum tritide of less than maximum specific activity was employed to introduce tritium, resulting in an H/T incorporation indicative of no kinetic isotope effect for the hydride/tritide reduction of a methyl benzoate. Copyright © 2005 John Wiley & Sons, Ltd.